Table 1 Demographic characteristics of the 70 Allo-HSCT recipients and risk factors for TB occurrence.

Demographic characteristics

27.5

9–60

29

9–65

Age

0.988

Sex

0.923

Male

9

64.29%

36

64.29%

Female

5

35.71%

20

35.71%

Underlying disease

0.983

Acute lymphoblastic leukaemia

3

21.43%

24

42.86%

Acute myeloblastic leukaemia

8

57.14%

20

35.71%

hybrid acute leukemia

1

7.14%

1

1.79%

Myelodysplastic syndrome

0

0.00%

6

10.71%

Chronic myeloid leukaemia

1

7.14%

2

3.57%

Aggressive lymphoma

1

7.14%

2

3.57%

myelofibrosis

0

0.00%

1

1.79%

Donor type

0.437

Unrelated donor

3

21.43%

9

16.07%

Haploidentical-related donor

8

57.14%

31

55.36%

Matched sibling donors

3

21.43%

16

28.57%

ATG given as conditioning

12

85.71%

41

73.21%

0.305

Conditioning intensity

0.774

MAC

13

92.86%

52

92.86%

RIC

1

7.14%

4

7.14%

GVHD prophylaxis

CSA based

5

35.71%

42

75.00%

0.344

FK 506 based

9

64.29%

14

25.00%

0.009

TB occurrence (months after HSCT)

6.95

1.54–32.46

N/A

3-year overall survival after HSCT

8

57.14%

43

76.79%

0.102

NRM at 3 years after HSCT

5

30.36 ± 13.55%

3

5.39 ± 3.06%

0.002

aGVHD (%)

0.013

Grades0–1

5

35.71%

41

73.21%

Grades2–4

9

64.29%

15

26.79%

*cGVHD (%) group after HSCT ≥100d

0.033

none-mild

4

40%

32

80%

moderate-severe

6

60%

8

20%

Cytomegalovirus viremia

11

78.57%

30

53.57%

0.123

Epstein Barr virus viremia

13

92.86%

30

53.57%

0.032

Invasive fungal disease

11

78.57%

13

23.21%

0.012

Follow-up duration, median months (range)

18.27

3.93–88.21

27.14

3.89–87.93

0.219

Patients who died(range)

12.05

3.93–39.79

13.93

3.89–51.86

Patients alive at last follow-up(range)

42.02

13.43–88.21

43.07

11.04–87.93